JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. [electronic resource]
Producer: 20160512Description: 14329-43 p. digitalISSN:- 1949-2553
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride -- pharmacology
- Female
- Humans
- Janus Kinase 2 -- antagonists & inhibitors
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- Pyrrolidines -- pharmacology
- Sulfonamides -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.